Cargando…

Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors

Chimeric antigen receptor (CAR)-T cells have enormous potentials for clinical therapies. The CAR-T therapy has been approved for treating hematological malignancies. However, their application is limited in solid tumors owing to antigen loss and mutation, physical barriers, and an immunosuppressive...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tao, Yu, Shao-kun, Xiang, Yan, Lu, Kai-Hua, Sun, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315443/
https://www.ncbi.nlm.nih.gov/pubmed/35903099
http://dx.doi.org/10.3389/fimmu.2022.936496